OCT 03, 2016 9:23 AM PDT

Metastatic Tumors Outsmart the Immune System

WRITTEN BY: Kara Marker
Why can the immune system recognize and attack primary tumors but not metastatic tumors? Researchers from the University of British Columbia, in collaboration with the Vancouver Prostate Centre, have the answer.
Biopsy of a highly differentiated squamous cell carcinoma of the mouth.
According to results from a study of human cancer patients, some individuals with prostate or renal cancer tumors showed an exceptional loss of an immune protein called interleukin-33 (IL-33). Without IL-33, cancer cells were able to “hide” from the immune system, and these patients were more likely to see their cancer return within five years.

After further investigating the role of IL-33 in immune evasion by cancer cells, researchers saw that effector T lymphocytes responsible for targeting tumors, like cytotoxic T cells, rely on IL-33 as a signal for denoting if a cell is cancerous. "IL-33 could be among the first immune biomarkers for prostate cancer and we are planning to examine this in a larger sample size of patients," said first author Iryna Saranchova.

The loss of IL-33 occurs in epithelial carcinomas, the cancers that initially develop in the lining of organs: prostate, kidney, breast, lung uterine, cervical, pancreatic, skin, and many more. Compared to other interleukins in the same family, IL-33 has unique intracellular and extracellular features. Inside the cell, IL-33 helps maintain barrier function by regulating gene expression, and outside the cell IL-33 is in charge of immune defense and repair mechanisms while simultaneously triggering the differentiation of helper T cells during the adaptive immune response.

IL-33 also works through a protein complex called major histocompatibility complex (MHC) to alert circulating effector T lymphocytes to the presence of a cancer cell. In addition to signaling the presence of cancer, MHC binds peptide fragments derived from pathogens for display on the cell surface so T cells will be aware of a microbial invasion. Even if MHC is present and functioning, without IL-33, the signaling process is ineffective. 

For cancer patients with epithelial carcinomas, monitoring levels of IL-33 could be an effective way to track the progression of their cancer. Additionally, resupplying cancerous cells with IL-33 could help the immune system start to recognize and attack again, according to results from the study. More experiments will be conducted to confirm the efficacy and safety of this treatment in clinical trials.

The present study was recently published in the journal Scientific Reports.
 


Sources: The University of British Columbia, Nature Immunology, Immunobiology: The Immune System in Health and Disease 5th edition, Journal of Cellular Physiology
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
DEC 23, 2020
Immunology
COVID Survivors Stay Immune for at Least a Year
DEC 23, 2020
COVID Survivors Stay Immune for at Least a Year
Once the coronavirus enters the body, the immune system springs into action, producing antibodies that bind to and neutr ...
JAN 20, 2021
Immunology
Gut Bacteria's Poison Arrows Exposed
JAN 20, 2021
Gut Bacteria's Poison Arrows Exposed
Bacteria armed with toxin bombs and excruciating abdominal pains caused by raging inflammation in the gut. While the cau ...
FEB 10, 2021
Drug Discovery & Development
Black Men Respond Best to Immunotherapy for Prostate Cancer
FEB 10, 2021
Black Men Respond Best to Immunotherapy for Prostate Cancer
Researchers from Northwestern University have found that Black men and men of African ancestry respond better than men f ...
APR 19, 2021
Cell & Molecular Biology
Insight Into the Molecular Basis of Rheumatoid Arthritis
APR 19, 2021
Insight Into the Molecular Basis of Rheumatoid Arthritis
New research has shown how variants in an immune gene can lead to a high risk of developing the autoimmune disorder rheu ...
APR 21, 2021
Immunology
Human T Cells Can't Recognize COVID Mutants
APR 21, 2021
Human T Cells Can't Recognize COVID Mutants
Genetic variants of the SARS-CoV-2 virus have emerged and tightened their grip on global communities as the pandemic rag ...
MAY 06, 2021
Immunology
COVID Vaccines Don't Protect Everyone
MAY 06, 2021
COVID Vaccines Don't Protect Everyone
New research has revealed that COVID-19 vaccines may not work as effectively in those whose immune systems have been neg ...
Loading Comments...